Valneva SE: Growing travel enthusiasm increases demand for targeted vaccinations!
Before the journey begins, vaccination has already become part of the packing process for many people. Valneva offers suitable travel vaccines!
The potential approval of the Lyme disease vaccine could represent a growth driver!
Reading Time: 1 minute
Valneva SE (i.) is a biotechnology company specializing in vaccines for infectious diseases with high unmet medical needs. Notably, the company has already approved products in niche areas that even occupy market-leading positions. The core product portfolio includes established travel vaccines such as IXIARO for Japanese encephalitis and DUKORAL for the prevention of cholera. However, the centerpiece of the current marketing strategy is IXCHIQ, the world's first and only approved vaccine for the Chikungunya virus. With this product, Valneva addresses...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
